Protein markers for Alzheimer in the frontal cortex and cerebellum

Neurology

Volumn 63, Issue 8, 2004, Pages 1385-1392

  Verdile, G ^a,b   Gnjec, A ^a   Miklossy, J ^c,d   Fonte, J ^a   Veurink, G ^a   Bates, K ^a   Kakulas, B ^a   Mehta, P D ^e   Milward, E A ^a,f   Tan, N ^a   Lareu, R ^a   Lim, D ^a   Dharmarajan, A ^a   Martins, Ralph N ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

^c Temple University   (United States)

^d UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^e NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^f UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA CATENIN; PRESENILIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTAL CORTEX; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; ONSET AGE; PATHOGENESIS; PRESENILIN 1 GENE; PRIORITY JOURNAL;

EID: 7044224405     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000141848.45315.A6     Document Type: Article

References (40)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-766.
2. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease [see comments]. Nature 1991;349:704-706.
3. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease [see comments]. Nature 1995;375:754-760.
4. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995;376:775-778.
5. Nochlin D, van Belle G, Bird TD, Sumi SM. Comparison of the severity of neuropathologic changes in familial and sporadic Alzheimer's disease. Alzheimer Dis Assoc Disord 1993;7:212-222.
6. Lemere CA, Lopera F, Kosik KS, et al. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med 1996;2:1146-1150.
7. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease [see comments]. Nat Med 1996;2:864-870.
8. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996;17:1005-1013.
9. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice [see comments]. Nat Med 1997;3:67-72.
10. Xia WM, Zhang JM, Kholodenko D, et al. Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem 1997;272:7977-7982.
11. Borchelt DR, Ratovitski T, van Lare J, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997;19:939-945.
12. Cherny RA, Legg JT, McLean CA, et al. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem 1999;274:23223-23228.
13. Bates KA, Fonte J, Robertson TA, et al. Chronic gliosis triggers Alzheimer's disease-like processing of amyloid precursor protein. Neuroscience 2002;113:785-796.
14. Fonte J, Miklossy J, Atwood C, Martins RN. The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid-beta levels: resolubilization of amyloid-beta with transition metal iron chelators. J Alzheimers Dis 2001;3:209-219.
15. Verdile G, Martins RN, Duthie M, Holmes E, St. George-Hyslop PH, Fraser PE. Inhibiting amyloid precursor protein C-tenninal cleavage promotes an interaction with presenilin 1. J Biol Chem 2000;275:20794-20798.
16. Mehta PD, Dalton AJ, Mehta SP, Kim KS, Sersen EA, Wisniewski HM. Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci Lett 1998;241:13-16.
17. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000;57:100-105.
18. Roughton SA, Lareu RR, Bittles AH, Dharmarajan AM. Fas and Fas ligand messenger ribonucleic acid and protein expression in the rat corpus luteum during apoptosis-mediated luteolysis. Biol Reprod 1999;60:797-804.
19. Chan CW, Dharmarajan A, Atwood CS, et al. Anti-apoptotic action of Alzheimer A beta. Alzheimers Rep 1999;2:113-119.
20. Naslund J, Schierhorn A, Hellman U, et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA 1994;91:8378-8382.
21. Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998;57:1168-1174.
22. Smith MA, Perry G. What are the facts and artifacts of the pathogenesis and etiology of Alzheimer disease? J Chem Neuroanat 1998;16:35-41.
23. Guo K, Wolf V, Dharmarajan AM, et al. Apoptosis-associated gene expression in the corpus luteum of the rat. Biol Reprod 1998;58:739-746.
24. Niswender GD, Juengel JL, Suva PJ, Rollyson MK, McIntush EW. Mechanisms controlling the function and life span of the corpus luteum. Physiol Rev 2000;80:1-29.
25. Mann DM, Takeuchi A, Sato S, et al. Cases of Alzheimer's disease due to deletion of exon 9 of the presenilin-1 gene show an unusual but characteristic beta-amyloid pathology known as "cotton wool" plaques. Neuropathol Appl Neurobiol 2001;27:189-196.
26. Mann DM, Pickering-Brown SM, Takeuchi A, Iwatsubo T. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol 2001;158:2165-2175.
27. Wang HY, D'Andrea MR, Nagele RG. Cerebellar diffuse amyloid plaques are derived from dendritic Abeta42 accumulations in Purkinje cells. Neurobiol Aging 2002;23:213-223.
28. Fukutani Y, Cairns NJ, Rossor MN, Lantos PL. Purkinje cell loss and astrocytosis in the cerebellum in familial and sporadic Alzheimer's disease. Neurosci Lett 1996;214:33-36.
29. Klafki H, Abramowski D, Swoboda R, Paganetti PA, Staufenbiel M. The carboxyl termini of beta-amyloid peptides 1-40 and 1-42 are generated by distinct gamma-secretase activities. J Biol Chem 1996;271:28655-28659.
30. Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ. Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci USA 1996;93:13170-13175.
31. Hartmann T, Bieger SC, Bruhl B, et al. Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat Med 1997;3:1016-1020.
32. Greenfield JP, Tsai J, Gouras GK, et al. Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Proc Natl Acad Sci USA 1999;96:742-747.
33. Murphy MP, Hickman LJ, Eckman CB, Uljon SN, Wang R, Golde TE. γ-Secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid beta peptides of varying length. J Biol Chem 1999;274:11914-11923.
34. De Strooper B, Saftig P, Craessaerts K, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998;391:387-390.
35. Wolfe MS, Haass C. The role of presenilins in gamma-secretase activity. J Biol Chem 2001;276:5413-5416.
36. Wolozin B, Iwasaki K, Vito P, et al. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 1996;274:1710-1713.
37. Guo Q, Sopher BL, Furukawa K, et al. Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals. J Neurosci 1997;17:4212-4222.
38. Guo Q, Christakos S, Robinson N, Mattson MP. Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: reduced oxidative stress and preserved mitochondrial function. Proc Natl Acad Sci USA 1998;95:3227-3232.
39. Broe M, Shepherd CE, Milward EA, Halliday GM. Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol (Berl) 2001;101:616-624.
40. Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 1987;78:151-164.